288 related articles for article (PubMed ID: 6770987)
1. Treatment of superficial bladder cancer.
Morales A
Can Med Assoc J; 1980 May; 122(10):1133-8. PubMed ID: 6770987
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for local recurrence in patients with pTa/pT1 urinary bladder cancer.
Jancke G; Damm O; Rosell J; Jahnson S
Scand J Urol Nephrol; 2008; 42(5):417-21. PubMed ID: 18609266
[TBL] [Abstract][Full Text] [Related]
3. The management of superficial bladder cancer.
Dalbagni G
Nat Clin Pract Urol; 2007 May; 4(5):254-60. PubMed ID: 17483810
[TBL] [Abstract][Full Text] [Related]
4. The results of concurrent chemo-radiotherapy for recurrence after treatment with bacillus Calmette-Guérin for non-muscle-invasive bladder cancer: is immediate cystectomy always necessary?
Wo JY; Shipley WU; Dahl DM; Coen JJ; Heney NM; Kaufman DS; Zietman AL
BJU Int; 2009 Jul; 104(2):179-83. PubMed ID: 19154448
[TBL] [Abstract][Full Text] [Related]
5. Current concepts in the management of superficial bladder cancer.
Soloway MS
Arch Esp Urol; 1990; 43 Suppl 2():115-21. PubMed ID: 2129003
[No Abstract] [Full Text] [Related]
6. Should bladder biopsies be performed routinely after bacillus Calmette-Guérin treatment for high-risk superficial transitional cell cancer of the bladder?
Guy L; Savareux L; Molinié V; Botto H; Boiteux JP; Lebret T
Eur Urol; 2006 Sep; 50(3):516-20; discussion 520. PubMed ID: 16632184
[TBL] [Abstract][Full Text] [Related]
7. Does photodynamic transurethral resection of bladder tumour improve the outcome of initial T1 high-grade bladder cancer? A long-term follow-up of a randomized study.
Denzinger S; Wieland WF; Otto W; Filbeck T; Knuechel R; Burger M
BJU Int; 2008 Mar; 101(5):566-9. PubMed ID: 17986289
[TBL] [Abstract][Full Text] [Related]
8. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
Thalmann GN; Sermier A; Rentsch C; Möhrle K; Cecchini MG; Studer UE
J Urol; 2000 Dec; 164(6):2129-33. PubMed ID: 11061941
[TBL] [Abstract][Full Text] [Related]
9. The role of surgery in the multimodality treatment of bladder cancer.
Coptcoat MJ; Oliver RT
Cancer Surv; 1998; 31():129-47. PubMed ID: 15281321
[TBL] [Abstract][Full Text] [Related]
10. Restaging transurethral resection of high risk superficial bladder cancer improves the initial response to bacillus Calmette-Guerin therapy.
Herr HW
J Urol; 2005 Dec; 174(6):2134-7. PubMed ID: 16280743
[TBL] [Abstract][Full Text] [Related]
11. Diagnosis and treatment of superficial bladder cancer: an update.
Crawford ED
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):1-9. PubMed ID: 8727804
[TBL] [Abstract][Full Text] [Related]
12. High-risk superficial bladder cancer: intravesical therapy for T1 G3 transitional cell carcinoma of the urinary bladder.
Pham HT; Soloway MS
Semin Urol Oncol; 1997 Aug; 15(3):147-53. PubMed ID: 9394909
[TBL] [Abstract][Full Text] [Related]
13. New approaches to intravesical chemo-immunotherapy in superficial bladder cancer.
van der Meijden AP
Prog Clin Biol Res; 1992; 378():95-101. PubMed ID: 1301591
[No Abstract] [Full Text] [Related]
14. [The immunotherapy of bladder tumors and the immunoprophylaxis of disease recurrence].
Korovin AI; Savvin VT
Urol Nefrol (Mosk); 1996; (1):19-21. PubMed ID: 8659034
[TBL] [Abstract][Full Text] [Related]
15. [Adjuvant local BCG-immunotherapy in patients with urothel cancer of the bladder (author's transl)].
Flamm J; Grof F
Wien Med Wochenschr; 1981 Oct; 131(20):501-6. PubMed ID: 7314632
[TBL] [Abstract][Full Text] [Related]
16. Cystectomy in patients with high risk superficial bladder tumors who fail intravesical BCG therapy: pre-cystectomy prostate involvement as a prognostic factor.
Huguet J; Crego M; Sabaté S; Salvador J; Palou J; Villavicencio H
Eur Urol; 2005 Jul; 48(1):53-9; discussion 59. PubMed ID: 15967252
[TBL] [Abstract][Full Text] [Related]
17. Intravesical chemotherapy versus immunotherapy for superficial bladder cancer.
Huben RP
Semin Urol Oncol; 1996 Feb; 14(1 Suppl 1):17-22. PubMed ID: 8727806
[TBL] [Abstract][Full Text] [Related]
18. [Intravesical adjuvant chemotherapy for superficial bladder cancer -- results of a survey in Saxony].
Steinbach F; Schuster F
Aktuelle Urol; 2005 Aug; 36(4):337-41. PubMed ID: 16110407
[TBL] [Abstract][Full Text] [Related]
19. T2a transitional cell carcinoma of the bladder: long-term experience with intravesical immunoprophylaxis with bacillus Calmette-Guerin.
Volkmer BG; Gschwend JE; Maier SH; Seidl-Schlick EM; Bach D; Romics I
J Urol; 2003 Mar; 169(3):931-4; discussion 934-5. PubMed ID: 12576815
[TBL] [Abstract][Full Text] [Related]
20. [Results of adjuvant intravesical Bacillus Calmette-Guérin therapy for grade 3 superficial bladder cancer].
Yumura Y; Oogo Y; Takase K; Hamano A; Yamashita Y; Noguchi S; Satomi Y
Hinyokika Kiyo; 2004 Nov; 50(11):767-71. PubMed ID: 15628536
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
